Special Issue

Nanocarriers for Targeted Cancer Therapy in Personalised Nanomedicine

Message from the Guest Editors

This Special Issue highlights the development and use of nanocarriers for targeted therapies in personalised medicine. Innovative and precision-based strategies for cancer treatment, involving customised nanovectors, play a crucial role in addressing what is often referred to as the 'disease of the century'. In this scenario, personalised nanomedicine is an emerging and inherently interdisciplinary field, promoting the development of next-generation nano-tools for targeted therapy and diagnosis, such as nanoparticles, nanocapsules, and nanomicelles. The publication of original research articles and reviews in this Special Issue will contribute to advancing scientific knowledge in personalised nanomedicine and support the clinical translation of nanocarrier-based approaches in oncology.

Guest Editors

Prof. Dr. Stefano Leporatti

CNR NANOTEC—Istituto di Nanotecnologia, Via Monteroni, 73100 Lecce, Italy

Dr. Francesca Persano

Mathematics and Physics Department "Ennio De Giorgi", Università del Salento, Via Monteroni, 73100 Lecce, Italy

Deadline for manuscript submissions

25 April 2026

Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed

mdpi.com/si/243721

Journal of Personalized Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/jpm

Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed

mdpi.com/journal/jpm

About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on "omics"-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical
subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker
Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

MDPI